Cancer is one of the biggest killers, and currently there are few ways to predict and improve patient outcomes. It has been shown that through the microbiome you can determine which patients will respond to therapies, and by manipulating it you can improve the efficacy of drugs.There is the potential to improve current therapies simply through altering the microbiome.
The Cancer Microbiome Congress (Boston, USA, 8-9 May 2018) will bring together academics, physicians, senior pharma executives and biotechs to learn about the developments and network to improve treatments in future. Top industry speakers presenting at the congress include David Cook from Seres Therapeutics, the first company to develop live microbial therapeutics and Vancheswaran “Deepak” Gopalakrishnan from MD Anderson who published the groundbreaking paper identifying how the gut microbiome influences responses to Anti-PD1-Therapy.
Find out more about the full lineup of speakers, the full congress agenda and the registration link here.
Date: May 8th-9th 2018
Time: 2 Days
Venue: Hilton Boston Dedham, 25 Allied Drive, Dedham, MA, 02026, USA
Be aware that as a member of MVA you get 15% discount. Use the code MVA15.
Key questions being addressed at the congress include:
- What strategies are necessary to create a functional understanding of the interactions between commensal bacteria & cancer?
- Is the microbiome the missing key to immunotherapies?
- How can we integrate the fields of microbiology and oncology to translate research into viable cancer therapeutics?
- Do microbial therapeutics have the potential to be utilized as standalone therapies?
- How can we exploit the microbiome to modulate the immune system to create a new form of personalized medicine?
- Could “microbiome-on-a-chip” one day replace mouse models?
Others speakers at the congress include:
- James Goedert MD, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH
- Susan Erdman, Principal Research Scientist and Assistant Director, MIT
- Bruce Roberts, Chief Scientific Officer, Vedanta Biosciences
- Marina R Walther-Antonio, Ph.D., Assistant Professor, Microbiome Program, Mayo Clinic
- Dario A. Gutierrez, Immuno-Biology Lead, Merck
- Loïc Vincent, Head, Oncology & Immunology Research Partnerships, Takeda
